| 產(chǎn)品編號(hào) | bs-2190R |
| 英文名稱(chēng) | Cytokeratin 19 Rabbit pAb |
| 中文名稱(chēng) | 細(xì)胞角蛋白19抗體 |
| 別 名 | 40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_HUMAN; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd. |
 |
Specific References (10) | bs-2190R has been referenced in 10 publications.
|
| 研究領(lǐng)域 | 腫瘤 干細(xì)胞 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Human (predicted: Mouse,Rat,Rabbit,Pig,Cow,Chicken,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,Flow-Cyt=1μg /test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 44 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞漿 細(xì)胞膜 細(xì)胞外基質(zhì) |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Cytokeratin 19.: 101-200/403 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The protein encoded by this gene is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically expressed in the periderm, the transiently superficial layer that envelopes the developing epidermis. The type I cytokeratins are clustered in a region of chromosome 17q12-q21. Function: Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle. Subunit: Heterotetramer of two type I and two type II keratins. Interacts with PNN and the actin-binding domain of DMD. Interacts with HCV core protein. Tissue Specificity: Expressed in a defined zone of basal keratinocytes in the deep outer root sheath of hair follicles. Also observed in sweat gland and mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, ectocervical epithelium (at protein level). Expressed in epidermal basal cells, in nipple epidermis and a defined region of the hair follicle. Also seen in a subset of vascular wall cells in both the veins and artery of human umbilical cord, and in umbilical cord vascular smooth muscle. Observed in muscle fibers accumulating in the costameres of myoplasm at the sarcolemma in structures that contain dystrophin and spectrin. Similarity: Belongs to the intermediate filament family. SWISS: P08727 Gene ID: 3880 Database links: Entrez Gene: 3880 Human Entrez Gene: 16669 Mouse Omim: 148020 Human SwissProt: P08727 Human SwissProt: P19001 Mouse Unigene: 654568 Human Unigene: 439699 Mouse 結(jié)構(gòu)蛋白（Structural Proteins） CK-19細(xì)胞角蛋白-19(又稱(chēng)CYFRa21-1)主要用于腫瘤方面的研究，近年來(lái)大多用于消化系統(tǒng)惡性腫瘤的鑒別，有學(xué)者認(rèn)為：CK-19在胰腺干細(xì)胞分化過(guò)程中有細(xì)胞角蛋白19的表達(dá)，把細(xì)胞角蛋白19作為胰腺干細(xì)胞的標(biāo)志物。陽(yáng)性部位：主要在胞漿。 |
| 產(chǎn)品圖片 |
Sample:
Lane 1: A549 (Human) Cell Lysate at 30 ug
Lane 2: MCF-7 (Human) Cell Lysate at 30 ug
Lane 3: HepG2 (Human) Cell Lysate at 30 ug
Primary: Anti-Cytokeratin 19 (bs-2190R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 42 kD
Observed band size: 42 kD
Paraformaldehyde-fixed, paraffin embedded (Human stomach carcinoma); Antigen retrieval by microwave in sodium citrate buffer (pH6.0) ; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (3% BSA) at RT for 30min; Antibody incubation with (Cytokeratin 19) Polyclonal Antibody, Unconjugated (bs-2190R) at 1:400 overnight at 4℃, followed by conjugation to the secondary antibody (labeled with HRP)and DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Human cervical carcinoma); Antigen retrieval by microwave in sodium citrate buffer (pH6.0) ; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (3% BSA) at RT for 30min; Antibody incubation with (Cytokeratin 19) Polyclonal Antibody, Unconjugated (bs-2190R) at 1:400 overnight at 4℃, followed by conjugation to the secondary antibody (labeled with HRP)and DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Human liver carcinoma); Antigen retrieval by microwave in sodium citrate buffer (pH6.0) ; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (3% BSA) at RT for 30min; Antibody incubation with (Cytokeratin 19) Polyclonal Antibody, Unconjugated (bs-2190R) at 1:400 overnight at 4℃, followed by conjugation to the secondary antibody (labeled with HRP)and DAB staining.
Blank control:MCF-7.
Primary Antibody (green line): Rabbit Anti-Cytokeratin 19 antibody (bs-2190R)
Dilution: 1ug/Test;
Secondary Antibody : Goat anti-rabbit IgG-FITC
Dilution: 0.5ug/Test.
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20℃.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
Blank control:A549.
Primary Antibody (green line): Rabbit Anti-Cytokeratin 19 antibody (bs-2190R)
Dilution: 2μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody : Goat anti-rabbit IgG-AF647
Dilution: 1μg /test.
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 0.1% PBST for 20 min at room temperature. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
Blank control (blue line): Hela (fixed with 70% methanol (Overnight at 4℃) and then permeabilized with 90% ice-cold methanol for 20 min at -20℃).
Primary Antibody (green line): Rabbit Anti-Cytokeratin 19 antibody (bs-2190R),Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody (white blue line): Goat anti-rabbit IgG-PE,Dilution: 1μg /test.
Blank control(blue): MCF7(fixed with 2% paraformaldehyde (10 min) and then permeabilized with ice-cold 90% methanol for 30 min on ice). Primary Antibody: Rabbit Anti-Cytokeratin 19/FITC Conjugated antibody (bs-2190R /FITC), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA;
Isotype Control Antibody: Rabbit IgG/FITC(orange) ,used under the same conditions.
|
